Literature DB >> 9237038

Drug selection for optimal treatment of hypertension in the elderly.

E Shammas1, K Dickstein.   

Abstract

Progressive aging of the world's population means that choosing the most effective drugs for the elderly is becoming increasingly important. The treatment of hypertension in the elderly is complicated because of the need to consider altered pharmacokinetics, comorbidity and multiple drug therapy in these patients. Antihypertensive treatment in the elderly has important and documented beneficial effects. However, no single drug class is suitable as the first-choice therapy for all elderly patients. The most appropriate choice of an antihypertensive drug often depends on comparative adverse effect profiles and the presence of comorbid disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237038     DOI: 10.2165/00002512-199711010-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  38 in total

1.  Shanghai trial of nifedipine in the elderly (STONE).

Authors:  L Gong; W Zhang; Y Zhu; J Zhu; D Kong; V Pagé; P Ghadirian; J LeLorier; P Hamet
Journal:  J Hypertens       Date:  1996-10       Impact factor: 4.844

2.  The acute and chronic effects of losartan in heart failure.

Authors:  I Crozier; H Ikram
Journal:  J Hypertens Suppl       Date:  1995-07

Review 3.  Increased risk attributed to left ventricular hypertrophy in hypertension.

Authors:  F H Leenen
Journal:  Curr Opin Cardiol       Date:  1996-09       Impact factor: 2.161

4.  Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.

Authors:  V Kon; A Fogo; I Ichikawa
Journal:  Kidney Int       Date:  1993-09       Impact factor: 10.612

Review 5.  Hypertension in the elderly.

Authors:  N E Bennet
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

Authors:  D R Abernethy; J Gutkowska; L M Winterbottom
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

Review 8.  Treatment of hypertension in the elderly.

Authors:  A F Lever; L E Ramsay
Journal:  J Hypertens       Date:  1995-06       Impact factor: 4.844

9.  Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials.

Authors:  K A Pearce; C D Furberg; J Rushing
Journal:  Arch Fam Med       Date:  1995-11

10.  Potency of vascular risk factors as the basis for antihypertensive therapy.

Authors:  W B Kannel
Journal:  Eur Heart J       Date:  1992-12       Impact factor: 29.983

View more
  2 in total

Review 1.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

Review 2.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.